As of July this year, based on Biogen's most recent financial report, the company's trailing twelve months EPS is $10.16. During 2024, BIIB reported a per-share earnings of $11.21, which shows a rise compared to the EPS of $8.02 recorded in 2023. Biogen's EPS for the quarterly period ending on Mar 31, 2025 came in at $1.65.
The yearly earnings per share during 2024 was $11.21, a rise of 39.8% compared to $8.02 recorded in 2023. Over the quarter ending Mar 31, 2025, the earnings per share came in at $1.65, reflecting a 39.1% decline compared to the same quarter a year earlier. As of March 2025, the TTM EPS is $10.16. During 2023, the annual earnings per share was $8.02, representing a decrease of 61.7% compared to 2022.
Over the past 12 months, Biogen has recorded an earnings per share growth rate of -39.1% (YoY, quarterly). Over an extended period, the company recorded an average EPS annual growth rate of 2.4% per year for the last 3 years. In the last five years, the company had an average annual EPS growth of -18.7%. A ten-year view shows that BIIB has seen an average earnings per share growth of -1% per year.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
BIIB Biogen Inc | 13.23 | 39.8% | 2.4% | -18.7% |
JNJ Johnson & Johnson | 17.2 | -57.9% | -9.7% | 0.4% |
PFE Pfizer Inc | 18.43 | 273.7% | -28.7% | -13.2% |
GILD Gilead Sciences Inc | 23.28 | -91.6% | -57.5% | -38.3% |
AMGN Amgen Inc | 26.88 | -39.3% | -9.7% | -10.1% |
ABBV AbbVie Inc | 80.41 | -12.1% | -28.2% | -14.7% |
QGEN Qiagen NV | 111.28 | -74.7% | -44.7% | N/A |
BIO Bio-Rad Laboratories Inc | N/A | -199.5% | N/A | N/A |
ILMN Illumina Inc | N/A | -4.8% | N/A | N/A |
SGMO Sangamo Therapeutics Inc | N/A | 66.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.